drug
as of 2026-07-01NaBen®
at a glance
small molecule
Pre-approval / investigational in the US
Developed by SyneuRx International (Taiwan) Corp
3 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Investigational (via trials)
Trials
3
An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults
NCT03094429Phase 2, Phase 3Recruiting
Study to Evaluate Safety & Efficacy of NaBen® as Add-on Treatment for Schizophrenia in Adults
NCT02261519Phase 2, Phase 3Terminated
Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®
NCT01908192Phase 2, Phase 3Terminated
KOLs & investigators
1
Robert Findling, MDKOL score 8
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
trial
Study to Evaluate Safety & Efficacy of NaBen® as Add-on Treatment for Schizophrenia in Adults
trialPHASE2, PHASE3
trial
indication
indication
indication
indication
indication
KOL
Robert Findling, MD
personKOL score 8